[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbXs-3t44mf88OQqO1ptE1YTo7ClNwof-As7fa6kK5HU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":10,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"The Alfred",[4,6],"The Alfred E. Mann Foundation for Scientific Research",51,false,4,2,4308,28,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Heart Failure",8,{"name":18,"count":19},"Schizophrenia",7,{"name":21,"count":22},"Schizoaffective Disorder",6,{"name":24,"count":9},"HIV Infections",{"name":26,"count":9},"Major Depressive Disorder",{"name":28,"count":29},"Schizophreniform Disorder",3,{"name":31,"count":29},"Cystic Fibrosis",{"name":33,"count":29},"Human Papillomavirus",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02097706","A Novel Drug for Borderline Personality Disorder","2025-12","NMDA receptor antagonist",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05591677","D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)","2026-05-29","D-Cycloserine",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,77,98,142,177,202,220,238,264,282,308,341,359,377,395,413,431,449,467,485,503,527,551,576,602,620,638,663,688,706,733,751,776,801,819,844,862,887,905,927],{"intervention":39,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":71,"PHASE4":73,"NA":75},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":54,"soonestReadout":38},[63],{"nctId":36,"briefTitle":37,"status":64,"phases":65,"primaryCompletion":38,"completion":38,"start":66,"enrollment":67,"conditions":68,"interventions":70},"RECRUITING",[48],"2015-01",150,[69],"Borderline Personality Disorder",[39],{"trials":72,"activeCount":58},[],{"trials":74,"activeCount":58},[],{"trials":76,"activeCount":58},[],{"intervention":44,"totalTrials":54,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":80,"activeCount":58},[],{"trials":82,"activeCount":58},[],{"trials":84,"activeCount":54,"soonestReadout":43},[85],{"nctId":41,"briefTitle":42,"status":86,"phases":87,"primaryCompletion":43,"completion":43,"start":88,"enrollment":89,"conditions":90,"interventions":91},"ACTIVE_NOT_RECRUITING",[48],"2023-04-21",180,[26],[44],{"trials":93,"activeCount":58},[],{"trials":95,"activeCount":58},[],{"trials":97,"activeCount":58},[],{"intervention":99,"totalTrials":29,"cells":100},"Raloxifene hydrochloride",{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":140},{"trials":102,"activeCount":58},[],{"trials":104,"activeCount":58},[],{"trials":106,"activeCount":58},[],{"trials":108,"activeCount":58},[],{"trials":110,"activeCount":58},[111,121,130],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT00361543","Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia","COMPLETED",[50],"2014-12","2006-08",54,[18,21,28],[99],{"nctId":122,"briefTitle":123,"status":114,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT02354001","Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia",[50],"2019-01","2011-04",80,[18,21],[99],{"nctId":131,"briefTitle":132,"status":114,"phases":133,"primaryCompletion":125,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT01481883","Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?",[50],"2019-02","2012-01",13,[18,21,28],[139],"Raloxifene Hydrochloride",{"trials":141,"activeCount":58},[],{"intervention":143,"totalTrials":10,"cells":144},"Tibolone",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":175},{"trials":146,"activeCount":58},[],{"trials":148,"activeCount":58},[],{"trials":150,"activeCount":58},[],{"trials":152,"activeCount":58},[],{"trials":154,"activeCount":58},[155,166],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":160,"start":160,"enrollment":10,"conditions":161,"interventions":163},"NCT01368068","Investigation of Tibolone and Escitalopram in Perimenopausal Depression","TERMINATED",[50],"2012-07",[162],"Perimenopausal Depression",[143,164,165],"Escitalopram","Natvia",{"nctId":167,"briefTitle":168,"status":114,"phases":169,"primaryCompletion":170,"completion":170,"start":160,"enrollment":171,"conditions":172,"interventions":174},"NCT01470092","Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression",[50],"2017-12",120,[173],"Menopausal Depression",[143],{"trials":176,"activeCount":58},[],{"intervention":178,"totalTrials":54,"cells":179},"ivacaftor",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":200},{"trials":181,"activeCount":58},[],{"trials":183,"activeCount":58},[],{"trials":185,"activeCount":58},[],{"trials":187,"activeCount":58},[],{"trials":189,"activeCount":58},[190],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":116,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT01937325","CPET in CF Patients With One G551D Mutation Taking VX770","UNKNOWN",[50],"2016-12","2014-02",20,[31],[178],{"trials":201,"activeCount":58},[],{"intervention":164,"totalTrials":54,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":218},{"trials":205,"activeCount":58},[],{"trials":207,"activeCount":58},[],{"trials":209,"activeCount":58},[],{"trials":211,"activeCount":58},[],{"trials":213,"activeCount":58},[214],{"nctId":156,"briefTitle":157,"status":158,"phases":215,"primaryCompletion":160,"completion":160,"start":160,"enrollment":10,"conditions":216,"interventions":217},[50],[162],[143,164,165],{"trials":219,"activeCount":58},[],{"intervention":165,"totalTrials":54,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":236},{"trials":223,"activeCount":58},[],{"trials":225,"activeCount":58},[],{"trials":227,"activeCount":58},[],{"trials":229,"activeCount":58},[],{"trials":231,"activeCount":58},[232],{"nctId":156,"briefTitle":157,"status":158,"phases":233,"primaryCompletion":160,"completion":160,"start":160,"enrollment":10,"conditions":234,"interventions":235},[50],[162],[143,164,165],{"trials":237,"activeCount":58},[],{"intervention":239,"totalTrials":54,"cells":240},"Carvedilol",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":262},{"trials":242,"activeCount":58},[],{"trials":244,"activeCount":58},[],{"trials":246,"activeCount":58},[],{"trials":248,"activeCount":58},[],{"trials":250,"activeCount":58},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":58,"conditions":258,"interventions":260},"NCT00384566","A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure","WITHDRAWN",[50],"2008-04","2005-06",[15,259],"Chronic Obstructive Airway Disease",[239,261],"Metoprolol",{"trials":263,"activeCount":58},[],{"intervention":261,"totalTrials":54,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":58},[],{"trials":269,"activeCount":58},[],{"trials":271,"activeCount":58},[],{"trials":273,"activeCount":58},[],{"trials":275,"activeCount":58},[276],{"nctId":252,"briefTitle":253,"status":254,"phases":277,"primaryCompletion":256,"completion":256,"start":257,"enrollment":58,"conditions":278,"interventions":279},[50],[15,259],[239,261],{"trials":281,"activeCount":58},[],{"intervention":283,"totalTrials":54,"cells":284},"Bazedoxifene Acetate",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":306},{"trials":286,"activeCount":58},[],{"trials":288,"activeCount":58},[],{"trials":290,"activeCount":58},[],{"trials":292,"activeCount":58},[],{"trials":294,"activeCount":58},[295],{"nctId":296,"briefTitle":297,"status":193,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":305},"NCT04113993","Bazedoxifene -Treatment for Women With Schizophrenia",[50],"2025-12-31","2019-10-07",160,[18,303,304],"Schizophreniform Disorders","Schizo Affective Disorder",[283],{"trials":307,"activeCount":58},[],{"intervention":309,"totalTrials":54,"cells":310},"Intermittent, short infusion Ceftazidime",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":339},{"trials":312,"activeCount":58},[],{"trials":314,"activeCount":58},[],{"trials":316,"activeCount":58},[],{"trials":318,"activeCount":58},[],{"trials":320,"activeCount":58},[321],{"nctId":322,"briefTitle":323,"status":193,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":329},"NCT01667094","A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis",[50],"2017-07","2012-09",50,[31],[309,330,331,332,333,334,335,336,337,338],"Continuous infusion Ceftazidime","Intermittent, short infusion Meropenem","Continuous infusion Meropenem","Intermittent, short infusion Ticarcillin-clavulanate","Continuous infusion Ticarcillin-clavulanate","Intermittent, short infusion Cefepime","Continuous infusion Cefepime","Continuous infusion Piperacillin tazobactam","Intermittent, short infusion Piperacillin tazobactam",{"trials":340,"activeCount":58},[],{"intervention":330,"totalTrials":54,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":357},{"trials":344,"activeCount":58},[],{"trials":346,"activeCount":58},[],{"trials":348,"activeCount":58},[],{"trials":350,"activeCount":58},[],{"trials":352,"activeCount":58},[353],{"nctId":322,"briefTitle":323,"status":193,"phases":354,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":355,"interventions":356},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":358,"activeCount":58},[],{"intervention":331,"totalTrials":54,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":375},{"trials":362,"activeCount":58},[],{"trials":364,"activeCount":58},[],{"trials":366,"activeCount":58},[],{"trials":368,"activeCount":58},[],{"trials":370,"activeCount":58},[371],{"nctId":322,"briefTitle":323,"status":193,"phases":372,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":373,"interventions":374},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":376,"activeCount":58},[],{"intervention":332,"totalTrials":54,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":393},{"trials":380,"activeCount":58},[],{"trials":382,"activeCount":58},[],{"trials":384,"activeCount":58},[],{"trials":386,"activeCount":58},[],{"trials":388,"activeCount":58},[389],{"nctId":322,"briefTitle":323,"status":193,"phases":390,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":391,"interventions":392},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":394,"activeCount":58},[],{"intervention":333,"totalTrials":54,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":411},{"trials":398,"activeCount":58},[],{"trials":400,"activeCount":58},[],{"trials":402,"activeCount":58},[],{"trials":404,"activeCount":58},[],{"trials":406,"activeCount":58},[407],{"nctId":322,"briefTitle":323,"status":193,"phases":408,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":409,"interventions":410},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":412,"activeCount":58},[],{"intervention":334,"totalTrials":54,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":416,"activeCount":58},[],{"trials":418,"activeCount":58},[],{"trials":420,"activeCount":58},[],{"trials":422,"activeCount":58},[],{"trials":424,"activeCount":58},[425],{"nctId":322,"briefTitle":323,"status":193,"phases":426,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":427,"interventions":428},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":430,"activeCount":58},[],{"intervention":335,"totalTrials":54,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":447},{"trials":434,"activeCount":58},[],{"trials":436,"activeCount":58},[],{"trials":438,"activeCount":58},[],{"trials":440,"activeCount":58},[],{"trials":442,"activeCount":58},[443],{"nctId":322,"briefTitle":323,"status":193,"phases":444,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":445,"interventions":446},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":448,"activeCount":58},[],{"intervention":336,"totalTrials":54,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":465},{"trials":452,"activeCount":58},[],{"trials":454,"activeCount":58},[],{"trials":456,"activeCount":58},[],{"trials":458,"activeCount":58},[],{"trials":460,"activeCount":58},[461],{"nctId":322,"briefTitle":323,"status":193,"phases":462,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":463,"interventions":464},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":466,"activeCount":58},[],{"intervention":337,"totalTrials":54,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":483},{"trials":470,"activeCount":58},[],{"trials":472,"activeCount":58},[],{"trials":474,"activeCount":58},[],{"trials":476,"activeCount":58},[],{"trials":478,"activeCount":58},[479],{"nctId":322,"briefTitle":323,"status":193,"phases":480,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":481,"interventions":482},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":484,"activeCount":58},[],{"intervention":338,"totalTrials":54,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":488,"activeCount":58},[],{"trials":490,"activeCount":58},[],{"trials":492,"activeCount":58},[],{"trials":494,"activeCount":58},[],{"trials":496,"activeCount":58},[497],{"nctId":322,"briefTitle":323,"status":193,"phases":498,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":499,"interventions":500},[50],[31],[309,330,331,332,333,334,335,336,337,338],{"trials":502,"activeCount":58},[],{"intervention":504,"totalTrials":54,"cells":505},"Aspirin",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":525},{"trials":507,"activeCount":58},[],{"trials":509,"activeCount":58},[],{"trials":511,"activeCount":58},[],{"trials":513,"activeCount":58},[],{"trials":515,"activeCount":58},[516],{"nctId":517,"briefTitle":518,"status":114,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":524},"NCT01534026","Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study",[50],"2015-02","2012-03",12,[15],[504],{"trials":526,"activeCount":58},[],{"intervention":528,"totalTrials":54,"cells":529},"Nesiritide",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":547,"NA":549},{"trials":531,"activeCount":58},[],{"trials":533,"activeCount":58},[],{"trials":535,"activeCount":58},[],{"trials":537,"activeCount":58},[538],{"nctId":539,"briefTitle":540,"status":158,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":22,"conditions":545,"interventions":546},"NCT00562692","Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease",[49],"2009-07","2009-09","2007-09",[15],[528],{"trials":548,"activeCount":58},[],{"trials":550,"activeCount":58},[],{"intervention":552,"totalTrials":54,"cells":553},"Hypertonic saline 6% -",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":572,"NA":574},{"trials":555,"activeCount":58},[],{"trials":557,"activeCount":58},[],{"trials":559,"activeCount":58},[],{"trials":561,"activeCount":58},[562],{"nctId":563,"briefTitle":564,"status":114,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT00484263","The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis",[49],"2009-10","2007-12",40,[570],"Bronchiectasis",[552],{"trials":573,"activeCount":58},[],{"trials":575,"activeCount":58},[],{"intervention":577,"totalTrials":54,"cells":578},"Milrinone 6mg",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":580,"activeCount":58},[],{"trials":582,"activeCount":58},[],{"trials":584,"activeCount":58},[585],{"nctId":586,"briefTitle":587,"status":114,"phases":588,"primaryCompletion":116,"completion":116,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT01849094","Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone",[47,48],"2013-05",9,[592,15],"Healthy",[577,594,595],"milrinone 10mg ER","milrinone 14mg",{"trials":597,"activeCount":58},[],{"trials":599,"activeCount":58},[],{"trials":601,"activeCount":58},[],{"intervention":594,"totalTrials":54,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":614,"PHASE4":616,"NA":618},{"trials":605,"activeCount":58},[],{"trials":607,"activeCount":58},[],{"trials":609,"activeCount":58},[610],{"nctId":586,"briefTitle":587,"status":114,"phases":611,"primaryCompletion":116,"completion":116,"start":589,"enrollment":590,"conditions":612,"interventions":613},[47,48],[592,15],[577,594,595],{"trials":615,"activeCount":58},[],{"trials":617,"activeCount":58},[],{"trials":619,"activeCount":58},[],{"intervention":595,"totalTrials":54,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":623,"activeCount":58},[],{"trials":625,"activeCount":58},[],{"trials":627,"activeCount":58},[628],{"nctId":586,"briefTitle":587,"status":114,"phases":629,"primaryCompletion":116,"completion":116,"start":589,"enrollment":590,"conditions":630,"interventions":631},[47,48],[592,15],[577,594,595],{"trials":633,"activeCount":58},[],{"trials":635,"activeCount":58},[],{"trials":637,"activeCount":58},[],{"intervention":639,"totalTrials":54,"cells":640},"Estradiol",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":642,"activeCount":58},[],{"trials":644,"activeCount":58},[],{"trials":646,"activeCount":58},[647],{"nctId":648,"briefTitle":649,"status":114,"phases":650,"primaryCompletion":651,"completion":652,"start":653,"enrollment":89,"conditions":654,"interventions":656},"NCT00357006","A Definitive Estrogen Patch Study (ADEPT)",[48],"2011-10","2013-12","2006-07",[18,21,655],"Schizophreniform Disorder(Not in Manic Phase)",[639,639],{"trials":658,"activeCount":58},[],{"trials":660,"activeCount":58},[],{"trials":662,"activeCount":58},[],{"intervention":664,"totalTrials":54,"cells":665},"Tamoxifen",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":667,"activeCount":58},[],{"trials":669,"activeCount":58},[],{"trials":671,"activeCount":58},[672],{"nctId":673,"briefTitle":674,"status":114,"phases":675,"primaryCompletion":567,"completion":567,"start":676,"enrollment":7,"conditions":677,"interventions":680},"NCT00206544","Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?",[48],"2004-01",[678,679,21],"Bipolar Disorder","Mania",[664,681],"Progesterone",{"trials":683,"activeCount":58},[],{"trials":685,"activeCount":58},[],{"trials":687,"activeCount":58},[],{"intervention":681,"totalTrials":54,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":691,"activeCount":58},[],{"trials":693,"activeCount":58},[],{"trials":695,"activeCount":58},[696],{"nctId":673,"briefTitle":674,"status":114,"phases":697,"primaryCompletion":567,"completion":567,"start":676,"enrollment":7,"conditions":698,"interventions":699},[48],[678,679,21],[664,681],{"trials":701,"activeCount":58},[],{"trials":703,"activeCount":58},[],{"trials":705,"activeCount":58},[],{"intervention":707,"totalTrials":54,"cells":708},"Dornase Alfa",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":710,"activeCount":58},[],{"trials":712,"activeCount":58},[],{"trials":714,"activeCount":58},[715],{"nctId":716,"briefTitle":717,"status":114,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":725},"NCT01952470","Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.",[48],"2017-08-23","2013-10-31",32,[723,724],"Lung Transplant Infection","Lower Respiratory Tract Infection",[707,726],"Isotonic Saline.",{"trials":728,"activeCount":58},[],{"trials":730,"activeCount":58},[],{"trials":732,"activeCount":58},[],{"intervention":726,"totalTrials":54,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":736,"activeCount":58},[],{"trials":738,"activeCount":58},[],{"trials":740,"activeCount":58},[741],{"nctId":716,"briefTitle":717,"status":114,"phases":742,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":743,"interventions":744},[48],[723,724],[707,726],{"trials":746,"activeCount":58},[],{"trials":748,"activeCount":58},[],{"trials":750,"activeCount":58},[],{"intervention":752,"totalTrials":54,"cells":753},"Milrinone",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":755,"activeCount":58},[],{"trials":757,"activeCount":58},[],{"trials":759,"activeCount":58},[760],{"nctId":761,"briefTitle":762,"status":114,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT01956006","Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure",[47,48],"2017-05-10","2018-05-10","2013-10-01",26,[15],[752],{"trials":771,"activeCount":58},[],{"trials":773,"activeCount":58},[],{"trials":775,"activeCount":58},[],{"intervention":777,"totalTrials":54,"cells":778},"Raloxifene",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":780,"activeCount":58},[],{"trials":782,"activeCount":58},[],{"trials":784,"activeCount":58},[785],{"nctId":786,"briefTitle":787,"status":114,"phases":788,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":793},"NCT00206557","The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study",[48],"2007-04","2002-10",60,[18,21,28],[777,794],"Estradiol\u002Fdyhydroprogestrone",{"trials":796,"activeCount":58},[],{"trials":798,"activeCount":58},[],{"trials":800,"activeCount":58},[],{"intervention":794,"totalTrials":54,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":804,"activeCount":58},[],{"trials":806,"activeCount":58},[],{"trials":808,"activeCount":58},[809],{"nctId":786,"briefTitle":787,"status":114,"phases":810,"completion":789,"start":790,"enrollment":791,"conditions":811,"interventions":812},[48],[18,21,28],[777,794],{"trials":814,"activeCount":58},[],{"trials":816,"activeCount":58},[],{"trials":818,"activeCount":58},[],{"intervention":820,"totalTrials":54,"cells":821},"Oxytocin",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":823,"activeCount":58},[],{"trials":825,"activeCount":58},[826],{"nctId":827,"briefTitle":828,"status":193,"phases":829,"primaryCompletion":830,"start":135,"enrollment":831,"conditions":832,"interventions":834},"NCT01239888","Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study",[47],"2012-11",15,[833,26],"Depression",[820,835],"Oxytocin and Tibolone",{"trials":837,"activeCount":58},[],{"trials":839,"activeCount":58},[],{"trials":841,"activeCount":58},[],{"trials":843,"activeCount":58},[],{"intervention":835,"totalTrials":54,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":847,"activeCount":58},[],{"trials":849,"activeCount":58},[850],{"nctId":827,"briefTitle":828,"status":193,"phases":851,"primaryCompletion":830,"start":135,"enrollment":831,"conditions":852,"interventions":853},[47],[833,26],[820,835],{"trials":855,"activeCount":58},[],{"trials":857,"activeCount":58},[],{"trials":859,"activeCount":58},[],{"trials":861,"activeCount":58},[],{"intervention":863,"totalTrials":54,"cells":864},"Withdrawal of digoxin",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":866,"activeCount":58},[],{"trials":868,"activeCount":58},[],{"trials":870,"activeCount":58},[],{"trials":872,"activeCount":58},[],{"trials":874,"activeCount":58},[],{"trials":876,"activeCount":58},[877],{"nctId":878,"briefTitle":879,"status":114,"phases":880,"primaryCompletion":520,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":885},"NCT01398371","Digoxin Withdrawal in Stable Heart Failure",[51],"2015-06","2011-08",16,[15],[863,886],"Digoxin",{"intervention":886,"totalTrials":54,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":890,"activeCount":58},[],{"trials":892,"activeCount":58},[],{"trials":894,"activeCount":58},[],{"trials":896,"activeCount":58},[],{"trials":898,"activeCount":58},[],{"trials":900,"activeCount":58},[901],{"nctId":878,"briefTitle":879,"status":114,"phases":902,"primaryCompletion":520,"completion":881,"start":882,"enrollment":883,"conditions":903,"interventions":904},[51],[15],[863,886],{"intervention":906,"totalTrials":54,"cells":907},"Withdrawal of statin therapy",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":909,"activeCount":58},[],{"trials":911,"activeCount":58},[],{"trials":913,"activeCount":58},[],{"trials":915,"activeCount":58},[],{"trials":917,"activeCount":58},[],{"trials":919,"activeCount":58},[920],{"nctId":921,"briefTitle":922,"status":114,"phases":923,"primaryCompletion":116,"completion":116,"start":521,"enrollment":136,"conditions":924,"interventions":925},"NCT01554592","Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study",[51],[15],[906,926],"Statin therapy",{"intervention":926,"totalTrials":54,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":58},[],{"trials":932,"activeCount":58},[],{"trials":934,"activeCount":58},[],{"trials":936,"activeCount":58},[],{"trials":938,"activeCount":58},[],{"trials":940,"activeCount":58},[941],{"nctId":921,"briefTitle":922,"status":114,"phases":942,"primaryCompletion":116,"completion":116,"start":521,"enrollment":136,"conditions":943,"interventions":944},[51],[15],[906,926]]